All 90 patients achieved SVR post DAA therapies. DAA therapies are safe and efficacious for use in octogenarian patients with CHC, including those with compensated cirrhosis. Active octogenarians should be considered for DAA therapies if there are no contraindications to treatment. Our study is limited by sample size and few comorbidities. Larger series with diverse demographics will further validate our understanding of the efficacy, tolerability, and safety of DAA therapy in the Octogenarian population. We encourage all health care providers to consider DAA therapy in this population.